CliffBio
small molecule

ATRACURIUM BESYLATE

ATRACURIUM BESYLATE

Loss of exclusivity—loss of exclusivity
CompanyMeitheal Pharmaceuticals, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameATRACURIUM BESYLATE
Active ingredientATRACURIUM BESYLATE
Strength10MG/ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalFebruary 2012
Marketing statusRX

More from Meitheal Pharmaceuticals, Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ATRACURIUM BESYLATE patent cliff — loss of exclusivity — | CliffBio